HK1212448A1 - Methods and compositions for diagnosis of inflammatory liver disease - Google Patents

Methods and compositions for diagnosis of inflammatory liver disease

Info

Publication number
HK1212448A1
HK1212448A1 HK16100401.5A HK16100401A HK1212448A1 HK 1212448 A1 HK1212448 A1 HK 1212448A1 HK 16100401 A HK16100401 A HK 16100401A HK 1212448 A1 HK1212448 A1 HK 1212448A1
Authority
HK
Hong Kong
Prior art keywords
diagnosis
compositions
methods
liver disease
inflammatory liver
Prior art date
Application number
HK16100401.5A
Other languages
English (en)
Chinese (zh)
Inventor
Abdolamir Landi
Michael Houghton
Lorne D Tyrrell
Tim Lankisch
Tobias Weismueller
Michael Manns
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of HK1212448A1 publication Critical patent/HK1212448A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
HK16100401.5A 2012-09-07 2016-01-14 Methods and compositions for diagnosis of inflammatory liver disease HK1212448A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698412P 2012-09-07 2012-09-07
US201261718134P 2012-10-24 2012-10-24
PCT/IB2013/002611 WO2014037811A2 (en) 2012-09-07 2013-09-06 Methods and compositions for diagnosis of inflammatory liver disease

Publications (1)

Publication Number Publication Date
HK1212448A1 true HK1212448A1 (en) 2016-06-10

Family

ID=50237710

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100401.5A HK1212448A1 (en) 2012-09-07 2016-01-14 Methods and compositions for diagnosis of inflammatory liver disease

Country Status (7)

Country Link
US (3) US9535071B2 (ja)
EP (1) EP2893343B1 (ja)
JP (2) JP6401702B2 (ja)
CN (1) CN104797933A (ja)
CA (1) CA2883711A1 (ja)
HK (1) HK1212448A1 (ja)
WO (1) WO2014037811A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401702B2 (ja) 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
WO2017045691A1 (en) * 2015-09-16 2017-03-23 Herlev Hospital Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
CN106153893B (zh) * 2016-06-14 2018-01-16 浙江大学 唾液抗线粒体抗体m2型的酶联免疫检测试剂盒
WO2018129056A1 (en) * 2017-01-04 2018-07-12 The Research Foundation For The State University Of New York Biomarker detection device
JP6924600B2 (ja) 2017-04-10 2021-08-25 シスメックス株式会社 測定方法、測定装置、プログラム、演算式の取得方法および定性判定結果の表示方法
WO2019075109A1 (en) * 2017-10-11 2019-04-18 The Governors Of The Univeristy Of Alberta BIOMARKERS IN AUTOIMMUNE HEPATIC DISEASE
CN108931517A (zh) * 2018-07-16 2018-12-04 台州市第人民医院 白介素31在制备原发性胆汁性胆管炎诊断试剂或试剂盒中的应用
BR112021011897A2 (pt) * 2018-12-26 2021-08-31 Colgate-Palmolive Company Biomarcadores de deregulação de neutrófilos como diagnóstico para gengivite
WO2021211787A1 (en) * 2020-04-15 2021-10-21 Children's Hospital Medical Center Systems and methods for quantification of liver fibrosis with mri and deep learning

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020042386A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
EP1453958A1 (en) 2001-11-27 2004-09-08 Bayer HealthCare AG Regulation of human serine/threonine protein kinase
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
AU2003238057A1 (en) 2002-06-28 2004-01-19 Bayer Healthcare Ag Human receptor tyrosine kinase mertk
ES2347144T3 (es) 2002-08-30 2010-10-26 Biorexis Pharmaceutical Corporation Proteinas de fusion de la transferrina modificada que comprenden dominos aino o carboxilo de transferrina duplicados.
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
EP1664796B1 (en) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
DE602005017391D1 (de) 2004-06-24 2009-12-10 Yissum Res Dev Co Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US20110034396A1 (en) 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
WO2007038749A2 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
AU2007275737A1 (en) 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
KR20090074787A (ko) 2006-10-05 2009-07-07 센토코 오르토 바이오테크 인코포레이티드 섬유증 치료용 ｃｃｒ2 길항제
BRPI0717803A2 (pt) * 2006-10-06 2013-11-19 Nestec Sa Composições e ensaios multiplicadores para a medição de mediadores biológicos de saúde fisiológica
JP2010509234A (ja) 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
TW200914437A (en) 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US20100233079A1 (en) 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2010242840B2 (en) 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR20120044294A (ko) 2009-05-01 2012-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
IN2012DN02737A (ja) 2009-09-01 2015-09-11 Abbott Lab
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20120104239A (ko) * 2009-11-14 2012-09-20 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료에 대한 신속한 반응을 예측하기 위한 바이오마커
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP6401702B2 (ja) 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物

Also Published As

Publication number Publication date
US20170153251A1 (en) 2017-06-01
CA2883711A1 (en) 2014-03-13
EP2893343A4 (en) 2016-08-31
US10641780B2 (en) 2020-05-05
US9535071B2 (en) 2017-01-03
JP2015534636A (ja) 2015-12-03
CN104797933A (zh) 2015-07-22
JP6401702B2 (ja) 2018-10-10
US20180209992A1 (en) 2018-07-26
EP2893343B1 (en) 2019-11-20
US20150219664A1 (en) 2015-08-06
US9952226B2 (en) 2018-04-24
WO2014037811A2 (en) 2014-03-13
JP2019012077A (ja) 2019-01-24
WO2014037811A3 (en) 2014-05-01
EP2893343A2 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
HK1212448A1 (en) Methods and compositions for diagnosis of inflammatory liver disease
EP2836224A4 (en) COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
ZA201508059B (en) Compositions and methods of use of phorbol esters
BR112013032426A2 (pt) composições probióticas e métodos
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2665726A4 (en) COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
GB201303936D0 (en) Methods and Compositions for the Diagnosis of Alzheimers Disease
EP2841945A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING OF STROKE OR OTHER BRAINS
EP2667889A4 (en) WNT COMPOSITIONS AND METHODS OF USE THEREOF
EP2834638A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF A SEPSIS
EP2838880A4 (en) COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING
ZA201408059B (en) Compositions and methods for the treatment of inflammatory bowel disease
SG10201602147YA (en) Methods And Compositions For Predicting Response To Eribulin
IL236636A0 (en) Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
IL227924B (en) Preparations and methods of use for determining a4he
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
EP2741771A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP2726110A4 (en) COMPOSITIONS AND METHODS FOR METABOLIC IMAGING
HK1204339A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2875347A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF SEPSIS
HK1207155A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1203620A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IL239623A0 (en) Methods and preparations for administering oxybutynin